Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04907968
Title Study of Upifitamab Rilsodotin in Combination With Other Agent(s) in Participants With High-grade Serous Ovarian Cancer (UPGRADE)
Acronym UPGRADE
Recruitment Terminated
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Mersana Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.